Istanbul nightclub attack kills 39 in New Year carnage

January 1, 2017

Istanbul, Jan 1: Thirty-nine people, including many foreigners, were killed when a gunman reportedly dressed as Santa Claus stormed an Istanbul nightclub as revellers were celebrating the New Year, the latest carnage to rock Turkey after a bloody 2016.

Istanbul

The assailant shot dead a policeman and a civilian at the entrance to the Reina club, one of the city's most exclusive nightspots, and then went on a shooting rampage inside, Turkish officials said.

Interior Minister Suleyman Soylu said the attacker escaped and was now the target of a major manhunt, expressing hope the suspect "would be captured soon".

Soylu said in televised comments that of 21 victims who have been identified so far, 16 are foreigners and five are Turks. Another 69 people are being treated in hospital.

"The attacker - in the most brutal and merciless way - targeted innocent people who had only come here to celebrate the New Year and have fun," Istanbul governor Vasip Sahin said at the scene on the shores of the Bosphorus.

Many revellers threw themselves into the water in panic and efforts were under way to rescue them, NTV television said.

Dogan news agency said there were two gunmen dressed in Santa Claus outfits, although this has yet to be confirmed.

Television pictures showed party-goers - including men in suits and women in cocktail dresses - emerging from the nightclub in a state of shock.

Sahin said the attack began at 1:15 am today (local time), just after hundreds of revellers had seen in 2017 at the club in the Ortakoy district on the European side of the city.

"What happened today is a terror attack," he said.

Dogan reported that some witnesses claimed the assailants were "speaking Arabic" while NTV said special force police officers were still searching the club.

There has been no claim of responsibility.

The attack evoked memories of the November 2015 carnage in Paris when Islamic State jihadists went on a gun and bombing rampage on nightspots in the French capital, killing 130 people including 90 at the Bataclan concert hall.

From Sydney to Paris, Rio to London, security had been boosted over fears that the New Year festivities could present a target for violent extremists.

In Istanbul, at least 17,000 police officers were deployed and some, as is customary in Turkey, dressed themselves as Santa Claus as cover, according to television reports.

"Just as we were settling down, by the door there was a lot of dust and smoke. Gunshots rang out. When those sounds were heard, many girls fainted," professional footballer Sefa Boydas told AFP.

"They say 35 to 40 died but it's probably more because when I was walking, people were walking on top of people."

Dogan said there were at least 700 revellers at the elite club, where getting past the bouncers who seek out only the best dressed is notoriously hard.

Turkey has been hit by a wave of attacks blamed on Kurdish militants and IS jihadists and 2016 saw more attacks than any other year in the history of the country.

On December 10, 44 people were killed in a double bombing in Istanbul after a football match hosted by top side Besiktas, an attack claimed by the Kurdistan Freedom Falcons (TAK) seen as a radical offshoot of the outlawed PKK rebel group.

In June, 47 people were killed in a triple suicide bombing and gun attack at Istanbul's Ataturk airport, with authorities blaming IS.

And in one of the most brazen strikes, an off-duty policeman assassinated Russia's ambassador to Turkey in an Ankara art gallery less than two weeks ago.

"No terror attack will destroy our unity, or eradicate our fraternity or weaken Turkey's effective fight against terror," Justice Minister Bekir Bozdag wrote on Twitter.

Mainly Muslin Turkey's religious affairs agency Diyanet condemned the attack, saying the fact it took place in a nightclub "was no different to it being in a market or place of worship".

Turkey is still reeling from a failed July coup blamed by the government on the US-based Islamic preacher Fethullah Gulen that has been followed by a relentless purge of his alleged supporters from state institutions.

"Tragic start to 2017 in Istanbul," NATO Secretary General Jens Stoltenberg wrote on Twitter.

The White House condemned the "savagery" of the attack, with National Security Council spokesman Ned Price saying that Washington reaffirmed its support for its NATO ally "in our shared determination to confront and defeat all forms of terrorism".

The US embassy warned citizens that extremist groups are continuing "aggressive efforts to conduct attacks in areas where US citizens and expatriates reside or frequent."

Turkish President Recep Tayyip Erdogan, who is in Istanbul for the New Year, had been informed of the attack, local media said.

The shooting spree came as the Turkish army wages a four-month incursion in Syria to oust IS jihadists and Kurdish militants from the border area, suffering increasing casualties.

As is customary after such attacks in Turkey, the authorities slapped a broadcast ban on images from the incident.

Comments

Naren kotian
 - 
Sunday, 1 Jan 2017

Israel actions are totally justified ...democracies must understand how to deal with jihadist menace ...religion of piece ....while shooting ...attacker shouting religious slogans. . time has come to mercilessly attack ...bomb them ...sympathy torsidre bennige chaaku haako jana...death to Islamic state ....rip innocents party goers.

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 28,2020

Washington, Mar 28: A US-based lab has unveiled a portable test that can tell if someone has COVID-19 in as little as five minutes, it said in a statement Friday.

Abbot Laboratories said the US Food and Drug Administration (FDA) had given it emergency authorization to begin making the test available to healthcare providers as early as next week.

The test, which is the size of a small toaster and uses molecular technology, also shows negative results within 13 minutes, the company said in a press statement.

"The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said Abbot president and chief operating officer Robert Ford.

The test's small size means it can be deployed outside the "traditional four walls of a hospital in outbreak hotspots," Ford said, and Abbott is working with the FDA to send it to virus epicenters.

The test has not been cleared or approved by the FDA, and has only been authorized for emergency use by approved labs and healthcare providers, the company said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 4,2020

Jun 4: A malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in people in close contact with someone with the disease.

Results published Wednesday by the New England Journal of Medicine show that hydroxychloroquine was no better than placebo pills at preventing illness from the coronavirus.

The drug did not seem to cause serious harm, though -- about 40% on it had side effects, mostly mild stomach problems.

 “We were disappointed. We would have liked for this to work,” said the study leader, Dr. David Boulware, an infectious disease specialist at the University of Minnesota.

“But our objective was to answer the question and to conduct a high-quality study,” because the evidence on the drug so far has been inconclusive, he said.

Hydroxychloroquine and a similar drug, chloroquine, have been the subject of much debate since Trump started promoting them in March.

Hydroxychloroquine has long been used for malaria, lupus, and rheumatoid arthritis, but no large studies have shown it or chloroquine to be safe or effective for much sicker patients with coronavirus, and some studies have suggested the drugs may do harm.

Trump took a two-week course of hydroxychloroquine, along with zinc and Vitamin D, after two staffers tested positive for COVID-19, and had no ill effects, according to results of his latest physical released by his doctor Wednesday.

Federal regulators have warned against hydroxychloroquine's use except in hospitals and formal studies because of the risk of side effects, especially heart rhythm problems.

Boulware's study involved 821 people in the United States and Canada living with someone diagnosed with COVID-19 or at high risk of getting it because of their job -- doctors, nurses, ambulance workers who had significant exposure to a sick patient while not wearing full protective gear.

They were randomly assigned to get either the nutrient folate as a placebo or hydroxychloroquine for five days, starting within four days of their exposure. Neither they nor others involved in the research knew who was getting which pills.

After 14 days in the study, 12 per cent on the drug developed COVID-19 symptoms versus 14 per cent in the placebo group, but the difference is so small it could have occurred by chance, Boulware said.

“There's basically no effect. It does not prevent infection,” he said of the drug. Even if it were to give some slim advantage, “we'd want a much larger effect” to justify its use and risk of side effects for preventing illness, he said.

Results were no different among a subgroup of participants who were taking zinc or vitamin C, which some people believe might help make hydroxychloroquine more effective or fight the coronavirus.

There are some big caveats: The study enrolled people through the Internet and social media, relying on them to report their own symptoms rather than having them tracked in a formal way by doctors.

Participants were not all tested for the coronavirus but were diagnosed as COVID-19 cases based on symptoms in many cases. And not all took their medicines as directed.

The results “are more provocative than definitive,” and the drug may yet have prevention benefits if tried sooner or in a different way, Dr. Myron Cohen of the University of North Carolina at Chapel Hill wrote in a commentary in the journal.

Others were glad to see a study that had a comparison group and good scientific methods after so many weaker reports on hydroxychloroquine.

“This fits with everything else we've seen so far which suggests that it's not beneficial," said Dr. Peter Bach, director of a health policy center at Memorial Sloan Kettering Cancer Center in New York.

This study was in younger relatively healthy people, but the results “would make me very discouraged about trying to use this in older people” who are most vulnerable to serious illness from the coronavirus, Bach said.

“If it does work, it doesn't work very well.” Dr. Dan Culver, a lung specialist at the Cleveland Clinic, said there's still a chance that giving the drug sooner than four days after someone's exposure to the virus may help prevent illness.

But the study “takes 'home run' off the table” as far as hopes for the drug, he said.

The study was mostly funded by David Baszucki, founder of Roblox, a California-based game software company, and other private donors and the Minnesota university.

Boulware also is leading a study testing hydroxychloroquine for treating COVID-19. The study is finished and results are being analyzed now.

On Tuesday, the journal Lancet posted an “expression of concern” about a study it published earlier this month of nearly 15,000 COVID-19 patients on the malaria drugs that tied their use to a higher risk of dying in the hospital or developing a heartbeat problem.

Scientists have raised serious questions about the database used for that study, and its authors have launched an independent audit.

That work had a big impact: the World Health Organization suspended use of hydroxychloroquine in a study it is leading, and French officials stopped the drug's use in hospitals. On Wednesday, the WHO said experts who reviewed safety information decided that its study could resume.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.